Navigation Links
Sequenom Announces Formation of Ophthalmology Clinical Advisory Board
Date:10/14/2010

lans, expectations, and activities regarding the development and commercialization of diagnostic  tests, including its age-related macular degeneration (AMD) test under development, and the potential of the AMD test, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic based diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation and investigations and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sequenom to Present at Two Financial Conferences in September
2. Sequenom to Present at Two Financial Conferences in March
3. Sequenom Appoints Two New Board Members
4. SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia
5. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
6. SEQUENOM Announces Launch of MassARRAY Compact 96 System
7. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
8. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
9. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
10. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
11. Osteotech Announces Early Termination of HSR Waiting Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  Prima Biomed Ltd. (NASDAQ: PBMD ... to become a leader in the development of immunotherapeutic ... the final CVac data from the Phase II CAN-003 ... for a clinically meaningful improvement in Overall Survival ("OS") ... In the group of second remission patients ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... Germany (PRWEB) May 21, 2015 ... that its manufacturing facility in Worms, Germany has ... an independent subsidiary of the International Pharmaceutical Excipient ... Grace facilities that produce its SYLOID® FP brand ... received GMP certification, following the Curtis Bay, Maryland ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrine therapy and oncology, today announced the opening ... with cetrorelix pamoate for the treatment of benign prostatic ... more than 20 million men in the U.S. alone. ...
... ATLANTA, Georgia, June 10 , ... Elsevier / MC Strategies, a pioneer in ... to announce that five,Clinical e-Learning courses were named as winners ... International,Academy of the Visual Arts (IAVA). With thousands of entries ...
... , Three-of-Four Patients Surveyed Experience Daily Pain From ... the European League Against Rheumatism Annual Congress of ... Results from the Rheumatoid Arthritis: Insights, Strategies ... rheumatoid arthritis (RA) patients throughout Europe and Canada ...
Cached Biology Technology:AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 5Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 2Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 3Elsevier / MC Strategies Online Courses Named in the 15th Annual Communicator Awards 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 2New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 3New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 4New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 5New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives 6
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... CHICAGO , Sept. 16, 2013  AUTOTESTCON –  Marvin ... Systems ), a trusted provider of innovative test solutions ... company,s involvement in AUTOTESTCON 2013 . The 49th ... Chicago, Illinois for ATE leaders ...
... A new understanding of the essential role of gut microbes ... with some of the more significant health problems facing people ... a new analysis. Problems ranging from autoimmune disease to ... to immune dysfunction that begins with a "failure to communicate" ...
... He heads the Institute for Diabetes and Obesity (IDO) ... director of the Helmholtz Diabetes Center (HDC). The Alexander ... Diseases at the Technische Universitt Mnchen (TUM). His research ... of fat and sugar metabolism, with the objective of ...
Cached Biology News:Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 2Marvin Test Solutions Featured at AUTOTESTCON 2013 with Leading Armament Experts and Test Systems 3Gut microbes closely linked to proper immune function, other health issues 2Gut microbes closely linked to proper immune function, other health issues 3